AlphaCentric Advisors LLC Purchases Shares of 11,478 Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

AlphaCentric Advisors LLC purchased a new stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) in the 3rd quarter, according to its most recent filing with the SEC. The fund purchased 11,478 shares of the company’s stock, valued at approximately $287,000.

Several other institutional investors also recently bought and sold shares of the business. Harbor Capital Advisors Inc. acquired a new stake in shares of Kiniksa Pharmaceuticals during the 3rd quarter worth $2,438,000. Rice Hall James & Associates LLC increased its holdings in shares of Kiniksa Pharmaceuticals by 8.2% during the 3rd quarter. Rice Hall James & Associates LLC now owns 649,630 shares of the company’s stock worth $16,234,000 after buying an additional 49,000 shares during the last quarter. AMI Asset Management Corp acquired a new stake in shares of Kiniksa Pharmaceuticals during the 3rd quarter worth $1,281,000. China Universal Asset Management Co. Ltd. increased its holdings in shares of Kiniksa Pharmaceuticals by 65.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,810 shares of the company’s stock worth $195,000 after buying an additional 3,076 shares during the last quarter. Finally, Semanteon Capital Management LP acquired a new stake in shares of Kiniksa Pharmaceuticals during the 3rd quarter worth $551,000. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 17,000 shares of Kiniksa Pharmaceuticals stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $26.87, for a total value of $456,790.00. Following the transaction, the chief operating officer now owns 109,975 shares in the company, valued at approximately $2,955,028.25. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 17,000 shares of Kiniksa Pharmaceuticals stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $26.87, for a total transaction of $456,790.00. Following the transaction, the chief operating officer now directly owns 109,975 shares in the company, valued at approximately $2,955,028.25. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider John F. Paolini sold 60,692 shares of Kiniksa Pharmaceuticals stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $26.12, for a total transaction of $1,585,275.04. Following the transaction, the insider now owns 52,038 shares in the company, valued at approximately $1,359,232.56. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 112,692 shares of company stock worth $2,950,315. 54.57% of the stock is owned by insiders.

Kiniksa Pharmaceuticals Price Performance

Shares of NASDAQ:KNSA opened at $21.48 on Tuesday. Kiniksa Pharmaceuticals, Ltd. has a 12 month low of $14.12 and a 12 month high of $28.15. The stock’s 50 day moving average price is $25.40 and its 200 day moving average price is $22.53.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its earnings results on Tuesday, October 29th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.17). Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The firm had revenue of $112.21 million for the quarter, compared to the consensus estimate of $111.51 million. During the same period in the previous year, the firm earned ($0.20) EPS. Kiniksa Pharmaceuticals’s revenue for the quarter was up 67.4% on a year-over-year basis. Research analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.47 EPS for the current fiscal year.

Analyst Ratings Changes

KNSA has been the subject of a number of research analyst reports. Evercore ISI upped their price objective on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Wedbush raised their price objective on Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the company an “outperform” rating in a research report on Tuesday, July 23rd. Finally, Jefferies Financial Group started coverage on Kiniksa Pharmaceuticals in a research report on Friday, September 13th. They issued a “buy” rating and a $40.00 price objective on the stock. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Kiniksa Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $34.60.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.